Abstract
Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors
| Original language | English |
|---|---|
| Article number | 1100 |
| Number of pages | 18 |
| Journal | Vaccines |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 08 Jul 2022 |
Keywords
- antibiotic resistance
- cystic fibrosis
- mucosal immunity
- Pseudomonas aeruginosa
- vaccines
ASJC Scopus subject areas
- Immunology
- Pharmacology
- Drug Discovery
- Infectious Diseases
- Pharmacology (medical)
Access to Document
- Pseudomonas aeruginosa: recent advances in vaccine development
Copyright 2022 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.